Cautiously Optimistic Analyst Sentiment on Mereo BioPharma Group (MREO) Following Disappointing Phase 4 Data for Setrusumab
On December 30, 2025, TheFly reported that Jefferies downgraded Mereo BioPharma Group plc (NASDAQ:MREO) from ‘Buy’ to ‘Hold’.
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.35 | 4,500 | $1,575.00 | 9,356,371 | 2011-12-09 | Filing | |
| $0.35 | 3,000 | $1,050.00 | 9,040,471 | 2009-06-03 | Filing | |
| $0.35 | 3,400 | $1,190.00 | 9,043,471 | 2009-05-29 | Filing |